Sushant Meshram

Government Medical College

Nagpur

India

SCHOLARLY PAPERS

2

DOWNLOADS

514

TOTAL CITATIONS

2

Scholarly Papers (2)

1.

A Phase 2/3, Observer-Blind, Randomised, Controlled Study to Assess the Safety and Immunogenicity of SII-ChAdOx1 nCOV-19 (COVID-19 Vaccine) in Adults in India

Number of pages: 32 Posted: 09 Aug 2021
Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR)Indian Council of Medical Research (ICMR) - National Institute for Research in Tuberculosis, AstraZeneca Biopharmaceuticals, KEM Hospital Research Centre - Vadu Budruk, Post Graduate Institute of Medical Education & Research (PGIMER), JSS Academy of Higher Education and Research, Mahatma Gandhi Institute of Medical Sciences, Seth G S Medical College & KEM Hospital, B J Government Medical College and Sassoon General Hospitals, Bharati Vidyapeeth (Deemed to be University) - Department of Pediatrics, Jehangir Clinical Development Centre, Topiwala National Medical College & B. Y. L. Nair Hospital, Government Medical College, Directorate of Public Health and Preventive Medicine, Indian Council of Medical Research (ICMR) - Rajendra Memorial Research Institute of Medical Sciences, Andhra Medical College, Sri Ramchandra Institute of Higher Education and Research, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, PPD India Pvt Ltd, PPD Laboratories Inc, - Vaccine Sciences Department, Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR), AstraZeneca Pharmaceuticals - AstraZeneca R&D, Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR), Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd and Independent
Downloads 365 (178,898)
Citation 1

Abstract:

Loading...

2.

Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled Study

Number of pages: 31 Posted: 08 Jul 2022
Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR) - National AIDS Research Institute, Indian Council of Medical Research (ICMR) - National AIDS Research Institute, Dr. D. Y. Patil Medical College, Hospital & Research Centre - Dr. D. Y. Patil Medical College, Hospital & Research Centre, Students, Mahatma Gandhi Institute of Medical Sciences, Hamdard Institute of Medical Sciences & Research (HIMSR), University of Liverpool - School of Tropical Medicine, JSS Academy of Higher Education and Research, Institute of Medical Sciences & SUM Hospital, KLES Dr. Prabhakar Kore Hospital & M.R.C, KEM Hospital Research Centre - Vadu Budruk, Seth G S Medical College & KEM Hospital, Government Medical College, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), KIIT University - Kalinga Institute of Medical Sciences (KIMS), KIMS Hospital and Research Centre, Christian Medical College, Sahyadri Super Specialty Hospital, Pune, Acharya Vinoba Bhave Rural Hospital, Amrita Institute of Medical Science - Division of Infectious Disease, Noble Hospital, All India Institute of Medical Sciences (AIIMS), Bhopal, All India Institute of Medical Sciences (AIIMS), Gorakhpur, Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Novavax, Inc. - Clinical Immunology Laboratory, Novavax, Inc. - Clinical Immunology Laboratory, Novavax, Inc. - Clinical Immunology Laboratory, 360biolabs, Indian Council of Medical Research (ICMR), Indian Council of Medical Research–National AIDS Research Institute, Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR), Indian Council of Medical Research (ICMR), Serum Institute of India Private Ltd, Serum Institute of India Private Ltd, Indian Council of Medical Research (ICMR), Serum Institute of India Private Ltd, Serum Institute of India Private Ltd and Independent
Downloads 149 (429,634)
Citation 1

Abstract:

Loading...

SII-NVX-CoV2373, NVX-CoV2373, safety, immunogenicity, non-inferiority